Samsung Group is deepening its focus on antibody drug conjugates through a new investment in Chinese biotech firm Phrontline Biopharma.
The backing comes from the Life Science Fund operated by Samsung Biologics, Samsung Bioepis, and Samsung C&T, with management handled by Samsung Venture Investment Corp. Financial terms were not revealed.
ADCs have become one of the fastest growing areas in oncology because they combine targeted antibodies with potent chemotherapy payloads. Phrontline is developing next-generation ADCs built on dual antibodies and dual payloads, an approach aimed at improving precision and treatment effectiveness.
Samsung sees the investment as a way to expand research partnerships and position itself for future growth in the ADC market. The deal follows last month’s collaboration between Samsung Bioepis and Phrontline to co-develop and commercialize two ADC assets. As part of that partnership, Samsung received exclusive rights to Phrontline’s payload technology for potential use across its own pipeline.